The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable buzz within the market. A shift away from Schedule I status, often viewed as outdated and hindering innovation, https://getsocialnetwork.com/story6288284/marijuana-rescheduling-a-growth-catalyst